Cyclo Therapeutics, Inc. (Caroline Hastings, Benny Liu, Bryan Hurst, Gerald Cox and Sharon Hrynkow) Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Artikle: https://www.sciencedirect.com/science/article/pii/S109671922200419X
Great reivew on glycoconjugates, their synthesis and pharmaceutical applications from Scripps Research (Sachin S. Shivatare, PhD, Vidya Shivatare and Chi-Huey Wong)
We are always thrilled to see companies adjancing drugs in the field of glycochemistry, just as Palleon Pharmaceuticals. who recently announced patenting engineered human sialidase enzymes that restore antitumor immunity by degrading immunosuppressive sialoglycans on tumors and across immune cell types
Tetsumi Irie form Kumamoto University explains the differences in the mechanisms of action for HPBCD and HPGCD in the treatment of Niemann-Pick C.
Full article: https://doi.org/10.1248/yakushi.21-00215
The cyclodextrin-supported atherosclerosis treatment field is getting crowded. Here is a unique approach using polyethylene glycol succinate (TPGS)-CD, which was adsorbed on rHDL, then modified with Apo-Ai, and coated with hyaluronan to obtain HT-rHDL. Piece of cake!
China Pharmaceutical University
Full article on ScienceDirect
https://doi.org/10.1016/j.carbpol.2022.119632
Cyclo Therapeutics, Inc. goes for Phase 2b Study of Trappsol® Cyclo™ for treating early Alzheimer’s disease.
See full post…
A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford University, The National Institutes of Health, Leibniz Institute on Aging – Fritz Lipmann Institute (FLI), Ludwig-Maximilians-Universität München, Whitehead Institute for Biomedical Research, University of Virginia School of Medicine and David Sabatini!
Full article on nature.com
Funding of translational research, using blockchain, NFTs, and a decentralized ownership and decision-making platform? One thing is for sure, it is not a sci-fi anymore.
We are happy to report on the acceptance of Tamas Sohajda‘s new patent on the use of single isomer chemically modified cyclodextrin for treating lysosomal storage diseases. Sugammadex and similar compounds are mentioned as potential active ingredients in this patent.
A little business for today:
ZyVersa Therapeutics Inc., a clinical-stage specialty biopharmaceutical company developing, among others, a cyclodextrin drug candidate (VAR 200), announced an aggregate committed financing in support of the business combination at $10.0 million.
This investment will enable Zyversa to advance clinical evaluation of the cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress into Phase 1 trials – said Steve Glover and Daniel J. O’Connor
Read more on the ZyVersa website
